Actively Recruiting
Study of Tildrakizumab Effects on Immune Cells in Adults with Moderate to Severe Psoriasis
Led by University of California, San Francisco · Updated on 2026-06-04
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to study how the immune cells in the skin and blood of people with moderate to severe psoriasis respond to treatment with the IL-23 blocker tildrakizumab. The study is open-label and will include 10 participants to better understand changes in immune function related to psoriasis during treatment. Participants will receive tildrakizumab, an IL-23 inhibitor, as the experimental treatment. Before and during treatment, skin biopsies and blood samples will be collected for detailed molecular analysis to identify changes in immune cell activity. This study focuses on identifying immune signatures corrected by tildrakizumab. During the study, researchers will assess changes in psoriasis severity using the Psoriasis Area and Severity Index PASI score at the start and after 3 months of treatment. Participants will undergo biopsy and blood collection at specified time points for immune profiling. The total study duration covers at least 3 months of treatment with ongoing monitoring of immune function.
CONDITIONS
Brief Title
Psoriatic Immune Response to Tildrakizumab
Research Team
R
Raymond Cho, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
